Dual GIP and GLP-1 receptor agonism in type 2 diabetes
The Lancet (SURPASS-2) · 2021
A head-to-head trial found greater reductions in HbA1c and body weight for the dual agonist than for a selective GLP-1 receptor agonist, at comparable tolerability.
peptides
Tirzepatide10mg
$59.99
A dual GIP and GLP-1 receptor agonist widely used in metabolic research. Precisely filled, purity verified, and shipped protected.
- Purity
- ≥99% (HPLC)
- Form
- Lyophilized powder
- Vial
- 10mg
- Testing
- Third-party assayed
1
- Free shipping on orders $199+
- Unbranded, discreet packaging
From the literature
Tirzepatide research
Research articles about Tirzepatide
Weight outcomes in adults with obesity
New England Journal of Medicine (SURMOUNT-1) · 2022
Across 72 weeks, participants receiving the dual agonist saw mean body-weight reductions well beyond placebo, establishing GIP co-agonism as a distinct metabolic research pathway.
Summaries of published literature, provided for context only. Nothing here is medical advice, and this product is sold for laboratory research use only.
Pairs well with
Related research
Related products
Retatrutide 10mg
$89.99Triple-agonist research compound.
Cagrilintide 5mg
$74.99Long-acting amylin analogue.
BPC-157 5mg
$49.99Body protection compound.
GHK-Cu 50mg
$54.99Copper tripeptide complex.
Tirzepatide
$59.99